Overview

Study Of B7H3 CAR-T Cells in Treating Advanced Liver Cancer

Status:
Recruiting
Trial end date:
2027-02-10
Target enrollment:
Participant gender:
Summary
This is single center, open-label phase I/II, non-randomized study which will enroll patients with recurrent advanced hepatocellular carcinoma to evaluate the safety, feasibility, and efficacy of fully human B7H3 CAR-T in treating hepatocellular carcinoma.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
The Affiliated Hospital of Xuzhou Medical University
Collaborators:
IIT MediTech Co. Ltd
Xuzhou Medical University
Treatments:
Cyclophosphamide
Fludarabine